LXR agonism for CNS diseases: promises and challenges

Simple item page
dc.contributor.authorZhang, Ruiyi
dc.contributor.authorWuerch, Emily
dc.contributor.authorYong, V. W.
dc.contributor.authorXue, Mengzhou
dc.date.accessioned2024-04-21T00:04:58Z
dc.date.available2024-04-21T00:04:58Z
dc.date.issued2024-04-16
dc.date.updated2024-04-21T00:04:58Z
dc.description.abstractAbstract The unfavorable prognosis of many neurological conditions could be attributed to limited tissue regeneration in central nervous system (CNS) and overwhelming inflammation, while liver X receptor (LXR) may regulate both processes due to its pivotal role in cholesterol metabolism and inflammatory response, and thus receives increasing attentions from neuroscientists and clinicians. Here, we summarize the signal transduction of LXR pathway, discuss the therapeutic potentials of LXR agonists based on preclinical data using different disease models, and analyze the dilemma and possible resolutions for clinical translation to encourage further investigations of LXR related therapies in CNS disorders. Graphical Abstract
dc.identifier.citationJournal of Neuroinflammation. 2024 Apr 16;21(1):97
dc.identifier.urihttps://doi.org/10.1186/s12974-024-03056-0
dc.identifier.urihttps://hdl.handle.net/1880/118456
dc.identifier.urihttps://doi.org/10.11575/PRISM/43298
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleLXR agonism for CNS diseases: promises and challenges
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12974_2024_Article_3056.pdf
Size:
3.91 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.25 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications